Significant Weight Loss from GLP-1 Drugs Linked to Lower Risk of Chronic Conditions
Similar Articles
Study Finds Weight Loss via GLP-1 Medications Attracts More Stigma Than Diet and Exercise
GLP-1 Medications Linked to Reduced Psychiatric Hospitalizations and Sick Leave
Study Links GLP-1 Use in Diabetes and Obesity to Higher Bone-Related Condition Rates
Endoscopic Procedure Shows Promise in Preventing Weight Regain After GLP-1 Medication Use
Semaglutide Shows Significant Weight Loss Benefits for Older Adults with Obesity
A new study presented at the European Congress on Obesity shows that patients who lost at least 15% of their body mass index using GLP-1 medications had significantly lower risks of osteoarthritis, chronic kidney disease, and obstructive sleep apnea. The research, based on nearly 90,000 US patients, also found that those who gained weight had higher risks for several conditions. These findings highlight the potential long-term health benefits of substantial weight loss.
Facts First
- Patients losing at least 15% BMI had a 37% lower osteoarthritis risk compared to those losing less than 5%.
- A 69% lower risk of obstructive sleep apnea was observed in patients achieving the highest weight loss.
- Weight gain was linked to a 69% higher risk of heart failure compared to minimal weight loss.
- The study tracked nearly 90,000 US patients starting GLP-1 treatments like Ozempic, Wegovy, and Mounjaro.
- About half of patients discontinued their medication within the first year of treatment.
What Happened
Researchers led by Professor John Wilding from the University of Liverpool analyzed data from 89,718 US patients who started GLP-1 based medications between January 2021 and June 2024. The medications included semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), and liraglutide (Saxenda). The team tracked changes in body mass index (BMI) during the first year of treatment and monitored risks for osteoarthritis, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and heart failure through June 2025. During the first year, 15.8% of patients lowered their BMI by at least 15%, while 20.8% gained weight.
Why this Matters to You
If you or someone you know is considering or using a GLP-1 medication for weight management, this research suggests that achieving significant weight loss could substantially reduce your risk of developing other serious health conditions. The study found that patients who lost at least 15% of their BMI had a significantly lower risk of osteoarthritis, CKD, and OSA. Conversely, gaining weight while on these treatments appears to increase your risk for conditions like sleep apnea and heart failure. This data may help you and your doctor set realistic health goals and understand the broader benefits of treatment beyond weight reduction.
What's Next
The research team presented these findings at the European Congress on Obesity (ECO 2026), which could influence clinical guidelines and patient counseling. Further studies are likely to explore these associations over longer periods and in different populations. The high rate of medication discontinuation within one year noted in this study may also prompt investigations into improving treatment adherence to help more patients achieve these protective health benefits.